Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 33,591 matching trials from the live ClinicalTrials.gov search.
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Artesia, California • Kansas City, Missouri • St Louis, Missouri + 4 more
Conditions
Overweight, Obesity
Interventions
Zenagamtide, Semaglutide, Placebo (matched to semaglutide), Placebo (matched to zenagamtide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
45
States / cities
Lancaster, California • Palm Springs, California • Pomona, California + 40 more
Terminated Phase 2 Interventional Results available

A Study of IMR-687 in Subjects With Sickle Cell Disease

NCT04474314
Conditions
Sickle Cell Disease
Interventions
IMR-687, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 11 more
Conditions
Wounds and Injuries
Interventions
AR/101, Placebo
Drug
Lead sponsor
Arava Bio Tech Ltd.
Industry
Eligibility
25 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Solid Tumor, HNSCC, RCC, CRC
Interventions
SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
Biological
Lead sponsor
SparX Biotech(Jiangsu) Co., Ltd.
Other
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Conditions
Advanced Solid Tumors or Hematologic Malignancies
Interventions
APG-1387 for Injection
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan • San Antonio, Texas
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
62
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
Conditions
Late-onset Sepsis
Interventions
Ceftaroline Fosamil, Ampicillin, Aminoglycoside
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Days to 59 Days
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Completed Phase 1Phase 2 Interventional Results available

Mifepristone for the Prevention of Relapses of Alcohol Drinking

NCT02243709
Conditions
Alcohol Use Disorders (AUD)
Interventions
Mifepristone 600-mg/day or placebo for a week
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Advanced Solid Tumors, Malignant Neoplasm
Interventions
MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist, Histamine H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent), Epinephrine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Solid Tumor, Adult, Oncology
Interventions
TRE-515
Drug
Lead sponsor
Trethera
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Santa Monica, California • Huntersville, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Hoodia on Blood Pressure and Heart Function

NCT00693264
Conditions
Healthy
Interventions
Hoodia Gordonii, Placebo
Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Jackson, Mississippi
Completed Phase 2 Interventional Results available

AZD7268 Safety and Tolerability Study

NCT01020799
Conditions
Major Depressive Disorder
Interventions
AZD7268, Escitalopram, Placebo capsules, Placebo tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Garden Grove, California • San Diego, California + 14 more
Conditions
Reperfusion Injury, STEMI
Interventions
Bendavia (MTP-131), Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Port Orange, Florida • Detroit, Michigan • Omaha, Nebraska
Conditions
Epithelial Ovarian Cancer
Interventions
Intermittent Fasting, Neoadjuvant chemotherapy
Behavioral · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Autism
Interventions
Memantine - Extended Release (ER), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions
Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
Biological · Other · Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
Conditions
Juvenile Myoclonic Epilepsy
Interventions
JZP926 capsule, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
Conditions
Systemic Lupus Erythematosus
Interventions
BMS-986165, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 45 more
Conditions
Hypertension
Interventions
candesartan cilexetil (Atacand)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 6 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Conditions
Rheumatoid Arthritis
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Billerica, Massachusetts
Conditions
Ileostomy
Interventions
One Piece Drainable Pouch
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
6,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
84
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 74 more
Conditions
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
Interventions
ROC-101
Drug
Lead sponsor
AllRock Bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more